NASDAQ:OMER Investor Notice: Investigation over Possible Securities Laws Violations by Omeros Corporation
An investigation for investors in Omeros Corporation (NASDAQ:OMER) shares over potential securities laws violations by Omeros Corporation was announced.
San Diego, CA -- (SBWire) -- 10/22/2021 --An investigation was announced concerning potential securities laws violations by Omeros Corporation in connection with certain financial statements.
Investors who purchased shares of Omeros Corporation (NASDAQ: OMER), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Omeros Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Seattle, WA based Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. On October 1, 2021, Omeros Corporation (NASDAQ: OMER) announced that the U.S. Food and Drug Administration ("FDA") had identified deficiencies with the Company's Biologics License Application for its drug candidate narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), which "preclude discussion of labeling and post-marketing requirements/commitments at this time." Though the "FDA did not provide specific details of the deficiencies in its notification[,]" the Company stated that it "does not currently expect any resolution to occur by the October 17, 2021 target action date under the Prescription Drug User Fee Act (PDUFA)."
Those who purchased shares of Omeros Corporation (NASDAQ: OMER) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Media Relations Contact
Michael Daniels
Shareholders Foundation
1-858-779-1554
https://www.shareholdersfoundation.com/
View this press release online at: http://rwire.com/1347926